

Special Issue

Glioblastoma: Current Status and Future Prospects

Message from the Guest Editor

Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults. Despite aggressive treatment modality, the current standard treatment regimen only provides palliation with a median survival of less than 15 months and a 5-year survival rate of 5% after initial diagnosis. However, in recent years, there has been an emergence of large interest in the development of targeted therapies for glioblastoma owing to its profound levels of genomic aberrations. Major molecular-mediated therapeutic approaches consist of targeting various oncogenic pathway-encoding molecules, including EGFR, PI3K/AKT/mTOR, VEGF, MET, FGFR, BRAF, cell cycle, and TGF β . On the other hand, immunotherapies focus on the disruption of immune checkpoint molecules that are expressed in T cells or tumor cells, such as PD-1, PD-L1, CTLA-4, LAG-3, TIM3, and TIGIT. Given the complexity of genomic architecture and microenvironment composition in GBM, future target-mediated investigations could open up new opportunities for innovative treatments.

Guest Editor

Dr. Jason K. Sa

Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Republic of Korea

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/164540

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).